Acute effect of urapidil on peripheral serotonin metabolism
Language English Country Czech Republic Media print
Document type Clinical Trial, Controlled Clinical Trial, Journal Article
PubMed
2225876
Knihovny.cz E-resources
- MeSH
- Platelet Aggregation drug effects MeSH
- Antihypertensive Agents pharmacology MeSH
- Adult MeSH
- Hypertension drug therapy metabolism MeSH
- Platelet Aggregation Inhibitors pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Piperazines pharmacology MeSH
- Serotonin metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Clinical Trial MeSH
- Names of Substances
- Antihypertensive Agents MeSH
- Platelet Aggregation Inhibitors MeSH
- Piperazines MeSH
- Serotonin MeSH
- urapidil MeSH Browser
In a cross-over study, the effect of 25 mg urapidil infusion (U, Ebrantil 25, Byk-Gulden, FRG) on serotonin (5HT) metabolism and platelet aggregation (PA) was compared with the effect of placebo (P) in 7 patients with essential hypertension. No changes in 5HT and 5-hydroxyindolacetic acid (5HIAA) plasma levels and platelet 5HT content were observed. PA induced ex vivo by ADP decreased significantly. 5HIAA urinary excretion and fractional excretion (FE) increased, while 5HT renal metabolism changed only moderately. No changes in adrenaline and noradrenaline excretion were observed. In in vitro studies, U in therapeutic levels decreased ADP-induced PA and completely inhibited 5HT-induced PA (platelets of healthy volunteers). It is suggested that U has a direct antiaggregatory effect through 5HT2 receptors of platelets.
